Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

Petra J. Woestenberg; Audrey J. King; Birgit H.B. Van Benthem; Suzan Leussink; Marianne A.B. Van Der Sande; Christian J.P.A. Hoebe; Johannes A. Bogaards

doi:10.1093/infdis/jiz187

Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

Petra J. Woestenberg^*, Audrey J. King, Birgit H.B. Van Benthem, Suzan Leussink, Marianne A.B. Van Der Sande, Christian J.P.A. Hoebe, Johannes A. Bogaards

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

Original language	English
Pages (from-to)	1280-1285
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	221
Issue number	8
DOIs	https://doi.org/10.1093/infdis/jiz187
Publication status	Published - 28 Mar 2020

Keywords

Anal cancer
Human papillomavirus (HPV)
Human papillomavirus vaccine
Public health
Vaccine effectiveness

Access to Document

10.1093/infdis/jiz187

Cite this

Woestenberg, P. J., King, A. J., Van Benthem, B. H. B., Leussink, S., Van Der Sande, M. A. B., Hoebe, C. J. P. A., & Bogaards, J. A. (2020). Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands. Journal of Infectious Diseases, 221(8), 1280-1285. https://doi.org/10.1093/infdis/jiz187

@article{61a6c04bf11946b0b6157586c9094433,

title = "Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands",

abstract = "Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.",

keywords = "Anal cancer, Human papillomavirus (HPV), Human papillomavirus vaccine, Public health, Vaccine effectiveness",

author = "Woestenberg, {Petra J.} and King, {Audrey J.} and {Van Benthem}, {Birgit H.B.} and Suzan Leussink and {Van Der Sande}, {Marianne A.B.} and Hoebe, {Christian J.P.A.} and Bogaards, {Johannes A.}",

year = "2020",

month = mar,

day = "28",

doi = "10.1093/infdis/jiz187",

language = "English",

volume = "221",

pages = "1280--1285",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "8",

}

Woestenberg, PJ, King, AJ, Van Benthem, BHB, Leussink, S, Van Der Sande, MAB, Hoebe, CJPA & Bogaards, JA 2020, 'Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands', Journal of Infectious Diseases, vol. 221, no. 8, pp. 1280-1285. https://doi.org/10.1093/infdis/jiz187

Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands. / Woestenberg, Petra J.; King, Audrey J.; Van Benthem, Birgit H.B. et al.
In: Journal of Infectious Diseases, Vol. 221, No. 8, 28.03.2020, p. 1280-1285.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

AU - Woestenberg, Petra J.

AU - King, Audrey J.

AU - Van Benthem, Birgit H.B.

AU - Leussink, Suzan

AU - Van Der Sande, Marianne A.B.

AU - Hoebe, Christian J.P.A.

AU - Bogaards, Johannes A.

PY - 2020/3/28

Y1 - 2020/3/28

N2 - Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

AB - Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

KW - Anal cancer

KW - Human papillomavirus (HPV)

KW - Human papillomavirus vaccine

KW - Public health

KW - Vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=85074989345&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiz187

DO - 10.1093/infdis/jiz187

M3 - Article

C2 - 31100134

AN - SCOPUS:85074989345

SN - 0022-1899

VL - 221

SP - 1280

EP - 1285

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 8

ER -

Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this